Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Laekna's share price for the quarter that ended in Dec. 2023 was HK$19.9. Laekna's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 390.10 Mil. Therefore, Laekna's market cap for the quarter that ended in Dec. 2023 was HK$7,762.99 Mil.
Laekna's quarterly market cap
increased
from Dec. 2022 (HK$0.00 Mil) to Jun. 2023 (HK$6,577.09 Mil) and
increased
from Jun. 2023 (HK$6,577.09 Mil) to Dec. 2023 (HK$7,762.99 Mil).
Laekna's annual market cap
stayed the same
from Dec. 2021 (HK$0.00 Mil) to Dec. 2022 (HK$0.00 Mil) but then
increased
from Dec. 2022 (HK$0.00 Mil) to Dec. 2023 (HK$7,762.99 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Laekna's Enterprise Value for Today is HK$1,953.55 Mil.
Laekna Market Cap Historical Data
The historical data trend for Laekna's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Laekna Market Cap Chart
Laekna Annual Data
Trend
Dec21
Dec22
Dec23
Market Cap
-
-
7,762.99
Laekna Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Dec23
Market Cap
-
-
-
6,577.09
7,762.99
Competitive Comparison of Laekna's Market Cap
For the Biotechnology subindustry, Laekna's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laekna's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Laekna's Market Cap distribution charts can be found below:
* The bar in red indicates where Laekna's Market Cap falls into.
Laekna Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Laekna's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laekna (HKSE:02105) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Laekna Market Cap Related Terms
Thank you for viewing the detailed overview of Laekna's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02105 has been successfully added to your